ArticlePregnancy (Hoboken, N.J.)2026
Society for Maternal-Fetal Medicine Special Statement: Guidance to reduce racial disparities in substance use screening and biological testing in pregnancy at the delivery admission.
Article in Pregnancy (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Substance use complicates upward of 10% of US pregnancies. The Society for Maternal-Fetal Medicine, the American College of Obstetricians and Gynecologists, and the American Society of Addiction Medicine have jointly recommended universal screening for substance use during pregnancy using a validated tool, without recommending universal biological testing. Despite this recommendation, racial and ethnic differences in substance use screening and biological testing occur, representing disparate care and a quality gap. This Special Statement from the Society for Maternal-Fetal Medicine introduces a comprehensive strategy, grounded in principles of quality improvement, to address racial and ethnic disparities in substance use screening, with an emphasis on equitable and respectful care. Additionally, we propose a quality metric expressed as the percentage of patients who were screened for a substance use disorder using a validated tool during birth hospitalization, stratified by race, ethnicity, preferred language, and payor status. This quality metric and other related metrics could serve as the basis for quality improvement projects aimed at reducing racial disparities in substance use screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.